BACK

Pancreatic Trials

Clinical trial information


Select trial for more information

Area under investigation=true,Pancreatic cancer

CLARITY-PanTumor01 trial overview

Tumor

Claudin 18.2-positive advanced solid tumors (gastric/GEJ cancer, pancreatic adenocarcinoma, BTCs)

Trial Identifier

NCT06219941

Phase

II

Regimen

Sonesitatug vedotin; sonesitatug vedotin + chemotherapy

Visit ct.gov
Go

NCT07640295 trial overview

Tumor

Treatment-naïve metastatic PDAC harboring KRAS gene alterations

Trial Identifier

NCT07640295

Phase

Ib/III

Regimen

JAB-23E73 + nab-paclitaxel + gemcitabine

Visit ct.gov

Partnered (Jacobio) China only

Go

PETRA trial overview

Tumor

Advanced solid tumors (advanced/metastatic ovarian cancer, HR+/HER2- breast cancer, TNBC, pancreatic cancer, prostate cancer, NSCLC, SCLC, gastric cancer, biliary cancer, cervical cancer, endometrial cancer, CRC, bladder cancer)

Trial Identifier

NCT04644068

Phase

I/IIa

Regimen

Saruparib; saruparib + paclitaxel; saruparib + carboplatin ± paclitaxel; saruparib + T-DXd; saruparib + Dato-DXd; saruparib + camizestrant

Visit ct.gov

fam-trastuzumab deruxtecan-nxki in US only; trastuzumab deruxtecan in other regions of world.

Go

Some compounds herein refer to selected AstraZeneca pipeline products still under development. AstraZeneca pipeline products are investigational products and, as such, are not approved by the US Food & Drug Administration (FDA), the European Medicines Agency (EMA) or any other regulatory agency for the uses under investigation. Information regarding these investigational products should, under no circumstances, be regarded as a recommendation for their use or of their safety or efficacy.

This site is intended for US Healthcare Professionals.

Veeva ID: Z4-84958 US-109129 DE-92568 Last Updated October 20263/26
©2026 AstraZeneca. All rights reserved.